Autoreceptors

Transmitter receptors on or near presynaptic terminals (or varicosities) which are sensitive to the transmitter(s) released by the terminal itself. Receptors for the hormones released by hormone-releasing cells are also included.

Also Known As:

Networked: 282 relevant articles (7 outcomes, 21 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Albert, Paul R: 8 articles (01/2019 - 12/2004)
2.	Mann, J John: 5 articles (01/2018 - 05/2004)
3.	Daigle, Mireille: 4 articles (01/2019 - 12/2016)
4.	Hen, René: 4 articles (01/2019 - 01/2014)
5.	Parsey, Ramin V: 4 articles (01/2018 - 03/2013)
6.	Hamon, Michel: 4 articles (12/2008 - 05/2003)
7.	Newman-Tancredi, Adrian: 3 articles (04/2022 - 05/2012)
8.	Pittaluga, Anna: 3 articles (09/2019 - 03/2013)
9.	Usai, Cesare: 3 articles (09/2019 - 03/2013)
10.	Tanaka, Kenji F: 3 articles (01/2019 - 12/2016)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 06/01/2005 - "The aim of this study was to investigate the association between schizophrenia and the G861C polymorphism in the 5-HT1D(beta) autoreceptor gene. " 07/01/2004 - "The aim of the present study was to examine genetic association between schizophrenia and polymorphisms in the 5-HT1Dalpha (TaqI) and 5-HT1Dbeta (T261G and G861C) autoreceptor genes in ninety trios from Portugal. " 07/01/2004 - "Lack of association or linkage disequilibrium between schizophrenia and polymorphisms in the 5-HT1Dalpha and 5-HT1Dbeta autoreceptor genes: family-based association study." 07/01/1991 - "Following pharmacological findings in animal studies, it was postulated that a hyperactivity of dopaminergic neurons, which is possibly present in acute schizophrenia, may be reduced by autoreceptor stimulation. " 01/01/2014 - "Based on the findings on drug-naïve and drug-free patients, it may be hypothesized that schizophrenia initially is characterized by an impaired mechanism of D2 autoreceptor and heteroreceptor sensitization leading to sensitization instead of desensitization in response to increased levels of neostriatal DA. "
2.	Dyskinesias (Dyskinesia) 03/01/2012 - "Here, we review the evidence for serotonergic involvement in dyskinesias from animal and human data, and highlight some of the translational gaps which may explain why the success of serotonin autoreceptor agonists as anti-dyskinetic agents in experimental models has failed to be replicated in clinical trials." 05/01/1995 - "The pattern of the quinpirole response in reserpine-treated monkeys suggested that the impairments in delayed response and fine motor performance resulted from drug actions at D2 autoreceptors, while the improvement in delayed response performance, dyskinesias and "hallucinatory-like" behaviors resulted from actions at postsynaptic receptors. " 01/01/2019 - "Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia." 12/02/2010 - "Moreover, the dyskinesias were significantly attenuated by administration of a serotonin agonist, which activates the inhibitory serotonin autoreceptors and attenuates transmitter release from serotonergic neurons, indicating that graft-induced dyskinesias were caused by the dense serotonergic innervation engaging in false transmitter release. " 08/01/2005 - "If 5-HT1A autoreceptors regulate dopamine as well as serotonin release, in parkinsonian patients inhibition of striatal serotonergic neuron firing might help maintain more physiological intrasynaptic dopamine concentrations and thus ameliorate motor fluctuations and dyskinesias. "
3.	Mood Disorders (Mood Disorder) 04/01/2008 - "It is well established that D3Rs, acting as autoreceptors, inhibit DA synthesis and release, although lack of selective compounds have limited the progress in understanding D3Rs role in mood disorders. " 01/01/2014 - "Specifically, chronic stress significantly attenuates 5-HT neurotransmission and 5-HT1A autoreceptor sensitivity, and this effect could represent an endophenotypic hallmark for mood disorders. " 02/01/2012 - "The serotonin 1A (5-HT(1A)) autoreceptor is known to play a role in mood disorders and their treatments. " 03/01/2011 - "Serotonin (5-hydroxytryptamine, 5-HT) neurotransmission is negatively regulated by 5-HT1A autoreceptors on raphe neurons, and is implicated in mood disorders. " 05/01/2007 - "Based on these data, one may speculate that the 5-HT autoreceptor antagonist/5-HT transport inhibitor SB-649915-B will have therapeutic efficacy in the treatment of affective disorders with the potential for a faster onset of action compared to current selective serotonin reuptake inhibitors."
4.	Migraine Disorders (Migraine) 01/05/1996 - "In humans, 5-HT1D serotonin receptors represent terminal autoreceptors, and there is some evidence that 5-HT1D ligands may be useful in the treatment of migraine. " 06/01/1990 - "These data suggest that sumatriptan, when infused into the brain, inhibits the release of 5-HT by stimulating 5-HT autoreceptors and that the putative acute anti-migraine effects of sumatriptan are likely to be mediated by peripheral mechanisms."
5.	Overactive Urinary Bladder (Overactive Bladder) 06/01/2014 - "These results indicate that activation of 5-HT1A autoreceptors on the serotonergic neurons in the raphe nucleus may suppress duloxetine and PNS inhibition, suggesting that the coadministration of a 5-HT1A antagonist drug might be useful in enhancing the efficacy of duloxetine alone and/or the additive effect of PNS-duloxetine combination for the treatment of overactive bladder symptoms. "

Related Drugs and Biologics

1.	Serotonin (5 Hydroxytryptamine)
2.	5-HT1A Serotonin Receptor
3.	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)
4.	Ligands
5.	Reserpine (Serpasil)
6.	Serotonin Receptors
7.	Serotonin 5-HT1 Receptor Antagonists
8.	Muscarinic M1 Receptor
9.	Quinpirole
10.	beta Adrenergic Receptors

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Chemical Sympathectomy
4.	Injections
5.	Induced Hypothermia